Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Dementia Conference 2019

About Conference


It is our pleasure to welcome you to the Dementia Conferences 2019 in the long stretch of November 18-19, 2019 Johannesburg, South Africa. The gathering will be dealt with around the subject of "Promising Growth Towards Pinnacle in Dementia Science"

ME Conferences generally respects participants across the world to attend "14th Annual Conference on Dementia and Alzheimer's Disease" scheduled on November 18-19, 2019 at Johannesburg, South Africa which consolidates prompt keynote presentations, Oral talks, Poster presentations, and Exhibitions.

Dementia, including Alzheimer's affliction, is one of the best overall general prosperity challenges facing our age. Around the globe, no under 44 million people are living with dementia this number is depended upon to twofold by 2030 and more than triple by 2050 to 115 million. Dementia 2019 has been organized and realized according to the accreditation necessities and methodologies of the Accreditation Committee.

Can we cure Dementia?

Discovering a friend or family member has Alzheimer's or other types of dementia is Scary. One of the primary inquiry’s individuals inquires as to whether there is a cure or an approach to recouping? Not all memory loss is identified with Alzheimer's or dementia. There are different reasons you may encounter memory issues including thyroid issues, stretch, vitamin insufficiencies or certain medicines

There is currently no "cure" for dementia. In fact, because dementia is caused by different diseases it is impossible that there will be a solitary cure for dementia

Our conference raises the following questions at Abu Dhabi:

  • What do you think are the biggest public misconceptions of Alzheimer's disease?
  • Will science ever discover a cure for Alzheimer's?
  • What recent scientific advances in treating or understanding Alzheimer's would you say you are most amped up for?
  • How will these change the diagnosis of the disease?

Conference Highlights:

  • Alzheimer’s Diseases
  • Parkinson’s Diseases
  • Vascular Dementia
  • Childhood Trauma and Dementia
  • Neurovascular Dysfunction and Neurodegeneration
  • Molecular and Cellular Basis of Neurodegeneration
  • Neuroimaging Biomarkers
  • Structural Neuroimaging
  • Neurodegenerative Diseases
  • Fixing Genetic risk for Alzheimer’s
  • Medical Biotechnology and Alzheimer’s Disease

Sessions / Tracks

Track: Alzheimer’s Diseases

Alzheimer's disease is irreversible and decimates cerebrum cells, making thinking capacity and memory weaken. Alzheimer's infection is a dynamic, degenerative mind ailment and the most widely recognized type of dementia, a gathering of brain disorders that influence a man's memory, considering and capacity to connect socially. Dementia and Alzheimer's infection isn’t the same. Dementia is a general term used to depict indications that effect memory, execution of day by day exercises, and correspondence capacities. Alzheimer's infection is the most widely recognized kind of dementia. Alzheimer's illness isn't a typical piece of maturing. We are leading exploration into the part of aggravation in Alzheimer's sickness to discover potential focuses for remedial mediation. The Dominantly Inherited Alzheimer Network is the main aim to discover biomarkers for Alzheimer's Diseases that are perceptible some time before the underlying clinical side effects. Members experience cerebrum checks and clinical evaluations and give blood and spinal liquid to explore. Presently utilizing hereditary linkage ways to deal with endeavor to distinguish these modifier qualities, which may give helpful focuses to the treatment of Alzheimer's sickness.

•           Neuro-Degenerative Disease

•           Hereditary qualities in Alzheimer

•           Cholinergic and Amyloid Hypothesis

•           Infection Associated Complexities

•           Propelled Tests and Treatments

Track: Parkinson’s Diseases

Parkinson's ailment (PD) is an un ending and dynamic neurological disorders that influence engine work, causing bradykinesia, postural unsteadiness, inflexibility and tremor very still. Side effects grow progressively, making start finding troublesome. PD likewise has a few non-engine highlights, including psychological wellness issues, rest unsettling influences and autonomic aggravations. At introduce, there is no cure for PD. The treatment is, subsequently, gone from treating side effects. There are right now two fundamental ways to deal with enhanced dopaminergic action inside the mind: expanding dopamine emission with exogenous operators and focusing on related neurotransmission pathways. Levodopa is the regular metabolic antecedent of dopamine and is profoundly successful for treating PD indications. Side effects of Parkinson's Diseases are normally overseen utilizing a specific dopamine receptor agonist. While these medications are valuable in beginning time Parkinson's, they tend to lose viability in later sickness stages

  • Tremor (shaking) very still
  • Gradualness of development
  • The solidness of the appendages and body
  • Weakened parity

Track: Vascular Dementia

Vascular dementia is the second most regular reason for dementia after Alzheimer's Diseases. Vascular changes that begin in mind territories that assume a key part in putting away and recovering data may cause memory misfortune that looks especially like Alzheimer's illness. Vascular dementia is a decrease in intuition abilities caused by conditions that square or diminish blood stream to the brain, denying mind cells of fundamental oxygen and supplements. Deficient blood stream can harm and, in the end, dead cells anyplace in the body. The mind has one of the body's richest systems of veins and is particularly helpless. In vascular dementia, changes in speculation abilities now and then happen abruptly following strokes that square significant cerebrum veins. A developing number of specialists lean toward the expression "Vascular Cognitive Impairment (VCI)" to "vascular dementia”. A few examinations have discovered that vascular changes and other cerebrum irregularities may associate in ways that improve the probability of dementia finding. The analysis of dementia or gentle psychological impedance is affirmed by neurocognitive testing, which includes a few hours of composed or mechanized tests that give point by point assessment of reasoning abilities, for example, judgment, arranging, critical thinking, thinking and memory

•           Clinical Phenotype and Pathogenetic Mechanisms

•           Neuronal Dysfunction in Vascular Dementia

•           Clinical Diagnosis of Vascular Dementia

•           Anticipation of Risks in Vascular Dementia

•           Advances in Treatment of Vascular Dementia

Track: Childhood Trauma and Dementia

New research recommends there is a solid relationship between initial childhood trauma, for example, that accomplished by the stolen ages, and dementia. There is an expansive agreement demonstrating that childhood trauma is fundamentally associated with the improvement of sorrow. There is a solid connection between a high introduction to early life stress and affliction, that incorporates individuals that were a piece of the stolen ages, and the probability of being determined to have dementia sometime down the road. Psychic trauma is any psychological disorders that unexpectedly overpowers the ability to give a negligible feeling of wellbeing and integrative wholeness, bringing about overpowering nervousness or defenselessness, or its danger, and creating a continuing change in the psychic organization. Childhood trauma can influence mental and physical wellbeing into adulthood.

  • Youth Trauma and PTSD Symptoms
  • Mental Therapies
  • Youth injury with intellectual capacity in sound grown-ups
  • Post-awful pressure issue and Alzheimer's ailment

Track: Alzheimer Disease and Cellular Mechanisms

Most continuous endeavors to battle Alzheimer Disease (AD) are centered around treating its clinical symptoms, however the neuropathologic changes fundamental AD show up decades sooner and turn out to be basically irreversible when the sickness achieves its clinical stages. This requires treating AD at preclinical stages, which requires a superior comprehension of the essential instruments prompting Alzheimer Disease pathology. Alzheimer's infection (AD) is a complex hereditary issue that is the main source of dementia in the elderly. Atomic confirmation raised the presumptions that trafficking of the amyloid precursor protein (APP) is under control of insulin flagging. Most progressing endeavors to battle Alzheimer Disease (AD) are centered around treating its clinical side effects, however the neuropathologic changes fundamental AD show up decades sooner and turn out to be basically irreversible when the ailment achieves its clinical stages.

  • Lessened debilitation
  • Improved certainty
  • Upgraded rest inclinations
  • Extended mental and social prompting
  • Constrained social changes

Track: Neurovascular Dysfunction and Neurodegeneration

Vascular insults can start a course of Molecular event occasions prompting neurodegeneration, psychological disorders, and dementia. Here, the molecular mechanisms and cell in cerebral veins pathophysiological occasions prompting disturbance of the blood-cerebrum obstruction and cerebral blood stream dysregulation and the neurovascular unit, which all may add to the beginning and movement of dementia and Alzheimer's disease. From the most punctual phases of improvement, when cerebral neurogenesis and angiogenesis are weaved, to the finish of life, the interaction between neural frameworks and vascular of the cerebrum is basic in wellbeing and infection. Cerebral blood stream control is fundamental for ordinary mind work. The mammalian mind has developed an exceptional system for CBF control known as neurovascular coupling.

  • Lessens arrangement of AGEs for better nerve capacity and course
  • Backings solid nerves and veins
  • Backings nerve transmission

Track: Molecular Genetics and Biology of Dementia

Molecular biology research has considerably deepened our understanding of the pathophysiological basis of Alzheimer's dementia. Considerable progress has been made in our understanding of the genetics and molecular biology of dementia. Some genetic risk factors have been identified so far, but only a small proportion of AD cases can be explained by specific gene mutations. Genes may be related to disease in two ways: through autosomal-dominant mutations, in themselves sufficient to cause the disease alternatively, gene variations (polymorphisms) may indirectly increase disease risk without being sufficient in themselves to cause the disorder.

  • Atomic Genetics of Neurodegenerative Dementias
  • Human undeveloped cell models of dementia
  • Settling Genetic hazard for Alzheimer's

Track: Medical Biotechnology and Alzheimer’s Disease

Alzheimer's Disease as a dynamic and fatal neurodegenerative disease speaks to an immense neglected requirement for treatment. The low viability of current treatment techniques isn't just because of low medication intensity yet in addition because of the nearness of different hindrances in the conveyance courses. One of the fundamental boundaries is the blood brain boundary. The expanding predominance of Alzheimer's Diseases and the low viability of ebb and flow treatments have expanded the measure of research on unwinding of sickness pathways and advancement of treatment techniques. One of the fascinating regions for the last subject is biotechnology and their applications. Nanotechnology is a standout amongst the most vital field in biotechnology and has a noteworthy part in the improvement of novel remedial modalities with expanded adequacy. In the nanotechnology field, materials are designed with utilitarian association on the nanoscale. Every one of the materials are utilized for association and incitement of organic frameworks at the atomic level to instigate physiological reactions. One of the primary issues concerning the treatment of neurodegenerative diseases is identified with medicate conveyance.

  • Alzheimer sickness tranquilize disclosure
  • Atomic and Cellular Basis of Neurodegeneration
  • Antibody against Alzheimer's ailment
  • Science of Aging

Track: Neuroimaging Biomarker

Alzheimer's disease Biomarkers, with emphasis on cerebrospinal fluid biomarkers and neuroimaging. Mild Cognitive Impairment (MCI) of Neuroimaging-biomarkers allow an early diagnosis in preclinical stages of Alzheimer’s disease. Biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. The dynamic measures of these imaging biomarkers are used to predict the disease progression in the early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials.

  • Neuroimaging Biomarkers in Personalized Medicine
  • Neuroimaging Genetics

Track: Neurological Diseases

Neurological disorders are maladies of the focal and fringe sensory system. At the end of the day, spinal rope, cranial nerves, fringe nerves, nerve roots, autonomic sensory system and neuromuscular intersection. These disarranges incorporate epilepsy, Alzheimer illness and different dementias, cerebrovascular sicknesses including stroke, headache and other migraine issue, various sclerosis, Parkinson's infection, neuroinfectious, mind tumors, awful scatters of the sensory system because of head injury, and neurological issue due to hunger. Neurological manifestations may happen because of the contamination itself or because of a safe reaction. Countless individuals worldwide are influenced by neurological disarranges. Alzheimer's sickness is the most widely recognized reason for dementia and may add to 60– 70% of cases.

  • Birth deformities of the mind and spinal line
  • Cerebrum aneurysm
  • Cerebrum tumor
  • Cerebral paralysis
  • Ceaseless weakness disorder

Track: Neurodegenerative Diseases

Neurodegenerative sicknesses are crippling, and it is a heterogeneous gathering of disarranges of serious conditions that outcome in dynamic degeneration. Neurodegenerative maladies cause issues with development called ataxias, or mental working called dementias. Neurodegenerative infections happen when nerve cells in the mind or fringe sensory system lose work after some time and at last pass on. Although medicines may help diminish a portion of the physical or mental side effects related with neurodegenerative infections, there is right now no cure or approach to moderate ailment movement. The danger of being influenced by a neurodegenerative increment drastically with age. A greatly little extent under five level of neurodegenerative infections are caused by hereditary changes. This makes a basic need to enhance our comprehension of what causes neurodegenerative infections and grow new methodologies for treatment and counteractive action.

  • Cause and Symptoms
  • Ischemic Stroke
  • Hemorrhagic Stroke
  • Transient Ischemic Stroke
  • Diagnosis and awareness on Stroke

Track: Alzheimer’s and the Brain

The brain ordinarily therapists to some degree in solid maturing in any case, shockingly, does not lose neurons in huge numbers. In Alzheimer's sickness, be that as it may, harm is across the board, the same number of neurons quit working, lose associations with different neurons, and pass on. Alzheimer's disturbs forms fundamental to neurons and their systems, including correspondence, digestion, and repair. Acetylcholine is a neurotransmitter that is insufficient in individuals with Alzheimer's, the place beginning memory misfortune is trailed by more far reaching changes in considering and conduct that prompt lost freedom. Numerous molecular and cell changes happen in the mind of a man with Alzheimer's illness.

  • powerlessness to perceive articles and faces
  • trouble understanding scene without a moments delay
  • trouble with perusing content, known as Alexia

Track: Alzheimer’s Clinical Trials and Studies

To evaluate the safety and efficacy of an oral investigational drug in individuals who are asymptomatic and at-risk for Alzheimer's disease and investigating the effect of cranium infusion on Alzheimer's disease progression in individuals with prodromal or mild Alzheimer's disease. Presently the clinical trials and studies are mainly concentrating on Alzheimer’s Disease & Down Syndrome, aging to have the best chance of changing the outlook for people with dementia promising ideas must be driven through the development process and into clinical trials in people as quickly as possible.

  • Preliminary Match
  • Miami Jewish Health Systems Alzheimer's and Dementia Trials
  • Motivations to Participate in Clinical Trials
  • Fox Trial Finder

Track: Diagnostic Alzheimer

Doctors can't analyze Alzheimer's Disease until after death, when they can nearly inspect the brain under a magnifying instrument. However, they can utilize tests to decide out different conditions that may cause similar symptoms. Early, exact finding is advantageous for a few reasons. Starting treatment ahead of schedule in the illness procedure may help protect day by day working for quite a while, even though the hidden Alzheimer's procedure can't be ceased or switched. Alzheimer's dementia comes about because of the dynamic misfortune (degeneration) of brain cells. This movement may appear in an assortment of courses in brain scans. At present researchers are exploring a few ailment markers and demonstrative tests, for example, qualities, infection related proteins and imaging methods, which may precisely and dependably show whether you have Alzheimer's dementia or not. whatever, right now more research on these tests is important for future.

  • Changes in rest designs
  • Feeling ill humored, pulled back, or segregated
  • Absent mindedness about one's very own history
  • Being not able to review their own location or telephone number
  • Requiring help picking appropriate apparel for the season

Track: Dementia Care and Consulting

Caring for a person with dementia influences distinctive individuals in various ways. In any case, caring can also be both physically and rationally debilitating. It influences all aspects of your life and can influence you to feel separated, pushed and at times even discouraged. You may also have your own physical and psychological wellness needs, which you and others may neglect when you are tending to another person. There are numerous positive things about caring. These incorporate adapting new aptitudes, expanding on existing ones, reinforcing connections, having a feeling of pride in what you are doing, and supporting somebody who is imperative to you. Furthermore, because a man has dementia, it doesn't mean there won't in any case be great circumstances for you to share.

  • Managing Dementia Behavior
  • Dementia Risk and Preventions

 

 

Market Analysis

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

Report Includes:

  • An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
  • Analyses of global market trends, with data from 2014, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2020

Anti-Parkinson's Drugs: Global Market Analysis

The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1%, from 2017 to 2022.

  • Asia Pacific anti-Parkinson’s drugs market is expected to grow from $1.0 billion in 2017 to $1.4 billion in 2022 at a CAGR of 6.4% for the period 2017-2022.
  • North American anti-Parkinson’s drugs market is expected to grow from $1.3 billion in 2017 to $1.8 billion in 2022 at a CAGR of 7.0% for the period 2017-2022
  • Europe anti-Parkinson’s drugs market is expected to grow from $1.5 billion in 2017 to $1.9 billion in 2022 at a CAGR of 9.0% for the period 2017-2022

Global Anti-Parkinson’s Drugs Forecast Market, Through 2022:

Reasons for Doing This Study:

The global anti-Parkinson’s drugs market is growing due to a rise in the aging population, growing awareness, increasing health insurance reforms and constant research and development in anti-Parkinson’s drugs by pharmaceutical companies. These factors along with technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies used to monitor and treat patients diagnosed with Parkinson’s disease are expected to drive the anti-Parkinson’s drugs industry

Major Alzheimer’s Disease Journals Globally:

  • The Journal of the Alzheimer’s Association
  • International Journal of Alzheimer's Disease
  • Journal of Alzheimer’s Disease
  • Journal of Community Health Research
  • Asia Pacific Family Medicine
  • Journal of School of Public Health and Institute of Public Health Research
  • AIMS Public Health
  • An International Journal on Alzheimer’s Disease and Associated Disorders
  • African Journal of Primary Health Care & Family Medicine
  • Indian Journal of Community Medicine
  • The Global Voice on Dementia
  • International Journal of Family Medicine
  • National Journal of Community Medicine

Related Societies:

USA:

American Academy of Neurology; American Spinal Injury Association; American Epilepsy Society; American Association of Neurological Surgeons; Child Neurology Society; The American Clinical Neurophysiology Society; American Psychological Association‎; American surgical organizations‎; Medical and health professional associations in Chicago‎ ; American Academy of Family Physicians‎; American Association for Cancer Research; American dental organizations‎; American Psychiatric Association‎

 

European Societies:

European Neurological Society; World Federation of Neurology; International Brain Research Organization; World Stroke OrganizationMovement Disorders Society; American Academy of Neurology; Albanian Society of Neurology; Armenian Scientific-Practical Union of Neurologists; Austrian Society of Neurology; Belarusian Scientific Society of Neurologists; Bulgarian Society of Neurology; Croatian Neurological Society; Cyprus Neurological Society; Czech Neurological Society; Danish Neurological Society ; Estonian Ludwig puusepp Society of Neurologists & Neurosurgeons; Macedonian Society of Neurology; Finnish Neurological Association ; French Society of Neurology ; Georgian Society of Neurologists; German Society of Neurology Hellenic Neurological Society; Icelandic Neurological Society; Irish Institute of Clinical Neuroscience; Italian Society of Neurology; Lithuanian Neurological Association; Luxembourg Society of Neurology ; Moldovan Scientific Society of Neurologists; Montenegrin Neurological Association; Norwegian Neurological Association; Polish Neurological Society; Romanian Society of Neurology; All-Russian Society of Neurologists; Neurological Society of Serbia; Slovak Neurological Society; Slovenian Society of Neurology; Spanish Society of Neurology; Swedish Neurological Society; Swiss Society of Neurology ; Netherlands Society of Neurology ; Turkish Neurological Society; Scientific Society of Neurologists of the Ukraine; Association of British Neurologists; National Neurological Society of Uzbekistan

 

Asia & Middle East:

Turkish neurological Society; South Africa Neurological Society; Indonesia Pediatric Society; Romania Society of Neurology; Afghan Neurological Association; Bahrain Neurosciences Association; Chinese Neurological Society; Hong Kong Neurological Society; Indian Academy of Neurology; Indonesian Neurological Association; Iranian Neurological Association; Iraq Neurological Society; Israel Neurological Association; Japanese Society of Neurology; The Jordan Neurological Society; League of Neurologists of Kazakhstan; Korean Neurological Association; Kuwait Neurological Society; National Association of Neurologists of the Kyrgyz Republic ; Malaysia Society of Neuroscience; Mongolian Association of Neurologist; Myanmar Society of Neurology; Oman Neurology Society; Pakistan Society of Neurology; Palestinian Neurological Society; Philippian Neurological Society; Qatar Neuroscience Club; Saudi Neurological Society; Clinical Neuroscience society Singapore; Association of Sri Lankan Neurologist; Syrian Society of Neuroscience; Taiwan Neurological Society; The Neurological Society Of Thailand; Emirates Neuroscience Society; National Neurological Society of Uzbekistan; Vietnamese Association of Neurology; Yemeni Neuroscience Society

 

Related Conferences:

Past Conference Report

Dementia 2018

DEMENTIA 2018

Gratitude’s to all of our honorable speakers, conference attendees, and sponsors. DEMENTIA 2018

The conference was our best ever!

13th Annual Conference on Dementia and Alzheimer’s Disease, hosted by the ME Conferences Group were held during December 13-15, 2018 Abu Dhabi, UAE at Bab Al Qasr Hotel, Abu Dhabi, UAE with the theme “Making A Move on Dementia: New Answers to Old Questions”. Magnanimous response and active participation were received from the Editorial Board Members of Alzheimer’s Disease & Parkinsonism as well as from the Scientists, Doctors, Professors, Neurologists, Radiologists, Pharmaceutical Industries, Healthcare Industries, Researchers and Students from the field of Neurology, who made this event successful.

ME Conferences Group played host to a diverse panel of key members of the DEMENTIA 2018 community from research lab, industry, academia, and financial investment practices, discussing the future of Neurology, Alzheimer’s Diseases, Parkinson’s Diseases, Alzheimer Disease and Cellular Mechanisms, Molecular Genetics and Biology of Dementia, Dementia Care and Consulting. This event was really aimed for examining where the technology is going in the future and purpose of the event was to provide an opportunity for cross-fertilization and development of ideas, in this field.

Focusing on Alzheimer’s Diseases, Parkinson’s Diseases, Vascular Dementia, Childhood Trauma and Dementia, Alzheimer Disease and Cellular Mechanisms, Neurovascular Dysfunction and Neurodegeneration, Molecular Genetics and Biology of Dementia, Medical Biotechnology and Alzheimer’s disease, Neuroimaging Biomarker, Neurological Diseases, Neurodegenerative Diseases, Alzheimer’s and the Brain the three days of discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities.

DEMENTIA 2018 Organizing Committee would like to thank the Organizing Committee Member of the conference Ghulam Md Ashraf, King Abdulaziz University, Saudi Arabia who contributed a lot for the smooth functioning of this event.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by a series of lectures delivered by Honourable Guests and members of the Keynote forum.

The highlights of the meeting were the eponymous lectures, delivered by:

  • Abha Chauhan, NYS Institute for Basic Research in Developmental Disabilities, USA

  • Ganiyu Oboh, Federal University of Technology, Nigeria

  • Ved Chauhan, NYS Institute for Basic Research in Developmental Disabilities, USA

  • Sundas Hira, Riphah International University, Pakistan

  • Opeyemi Babatunde Ogunsuyi, Federal University of Technology, Nigeria

  • Malka Ceh, Sigmund Freud University, Austria

  • Satyaprakash Tiwari, Jamiyah Nursing Home, Singapore

  • Ghulam Md Ashraf, King Abdulaziz University, Saudi Arabia

  • Zahra Vahabi, Tehran University of Medical Sciences, Iran

  • Muhammad Asif Rasheed, COMSATS University Islamabad, Pakistan

  • Ahmed Saadeldin Hussein Hamed, Ain Shams University School of Medicine, Egypt

These talks were of great interest to the general Dementia and Alzheimer’s and were enormously informative.

13th Annual Conference on Dementia and Alzheimer’s disease was a great success with the support of the Journal of Dementia, Alzheimers Disease & Parkinsonism, and Journal of Neurological Disorders. We are happy to announce our 14th Annual Conference on Dementia and Alzheimer’s disease to be held during November 18-19, 2019 Johannesburg in South Africa.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date November 18-19, 2019

Speaker Opportunity

Supported By

Journal of Dementia Journal of Alzheimers Disease & Parkinsonism Journal of Neurological Disorders

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

mediapartner

Media Partner

mediapartner

Media Partner

Keytopics

  • Alzheimers
  • Alzheimers Disease
  • Alzheimers Disease And Dementia
  • Amyloid And Tau Imaging
  • Amyloid Protein In Dementia
  • Animal Models And Translational Medicine
  • Behavioural Problems In Alzheimers Disease
  • Biomarker Variables
  • Brain Disorders
  • Care And Quality Of Life
  • Care Practices In Dementia
  • Caregiver Support
  • Cognitive Training
  • Dementia
  • Dementia Care
  • Diagnosis And Symptoms
  • Education And Training Of Medical Professionals
  • EEG And Brain Mapping
  • Epilepsy
  • Frontotemporal Dementia
  • Functional Foods
  • Genetics In Dementia
  • Geriatrics And Cognitive Disorders
  • Imaging Animal Models
  • Imaging Correlates Of Clinical And Cognitive
  • Imaging Techniques
  • Managing Dementia
  • Mixed Dementia
  • Multi-infarct Dementia
  • Neuro Imaging
  • Neurodegenerative Diseases
  • Neurological Diseases
  • New Methods In Imaging
  • Non-pharmacological Interventions
  • Nursing And Care Practice
  • Parkinson Dementia
  • Parkinsons Disease
  • Pathophysiology Of Alzheimers Disease
  • Person Centered Care
  • Positron Emission Tomography
  • Post Stroke Dementia
  • Putting Scientific Knowledge Into Practice
  • Sleep And Dementia
  • SPECT Imaging
  • Stroke-related Dementia
  • Structural And Functional MRI
  • Traumatic Brain Injury
  • Treatment Of Alzheimers Disease
  • Vascular Dementia
  • White Matter And Dementia